for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

4d Pharma PLC

LBPS.OQ

Latest Trade

7.20USD

Change

0.01(+0.14%)

Volume

9,634

Today's Range

7.17

 - 

7.30

52 Week Range

6.09

 - 

15.50

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
7.19
Open
7.26
Volume
9,634
3M AVG Volume
33.09
Today's High
7.30
Today's Low
7.17
52 Week High
15.50
52 Week Low
6.09
Shares Out (MIL)
180.30
Market Cap (MIL)
118.82
Forward P/E
-4.85
Dividend (Yield %)
--

Next Event

4D Pharma PLC at Jefferies Next Generation IBD Therapeutics Summit (Virtual)

Latest Developments

More

4D Pharma PLC - Have Filed Registration Statement Of Which This Prospectus Forms Part With Respect To 22.4 Million Ordinary Shares Held By Shareholders

4D Pharma PLC says collaboration with Parkinson's UK

4D Pharma FY Diluted Loss/Share 22.8p

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About 4d Pharma PLC

4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.

Industry

Biotechnology & Drugs

Contact Info

9 Bond Court

LS1 2JZ

United Kingdom

+44.113.8950130

https://www.4dpharmaplc.com/

Executive Leadership

Axel Glasmacher

Non-Executive Independent Chairman of the Board

Duncan Joseph Peyton

Chief Executive Officer, Executive Director

Alexander James Stevenson

Chief Scientific Officer, Executive Director

Glenn Dourado

Chief Business Officer

Edgardo Baracchini

Non-Executive Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2018

0.0K

2020

0.0K

2021(E)

0.0K
EPS (GBp)

2018

-36.170

2019

-40.810

2020

-22.800

2021(E)

-13.600
Price To Earnings (TTM)
--
Price To Sales (TTM)
242.49
Price To Book (MRQ)
3.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.55
LT Debt To Equity (MRQ)
2.36
Return on Investment (TTM)
-182.79
Return on Equity (TTM)
-154.55

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up